CaltechAUTHORS
  A Caltech Library Service

Cyclic cell state transition is associated with the adaptive resistance to BRAF inhibition in melanomas

Su, Yapeng and Lu, Xiang and Li, Guideng and Robert, Lidia and Ng, Alphonsus and Xue, Min and Ribas, Antoni and Baltimore, David and Levine, Raphael and Wei, Wei and Heath, James R. (2018) Cyclic cell state transition is associated with the adaptive resistance to BRAF inhibition in melanomas. In: 256th American Chemical Society National Meeting & Exposition, 19-23 August 2018, Boston, MA. http://resolver.caltech.edu/CaltechAUTHORS:20181109-142044662

Full text is not posted in this repository. Consult Related URLs below.

Use this Persistent URL to link to this item: http://resolver.caltech.edu/CaltechAUTHORS:20181109-142044662

Abstract

Cancers commonly develop resistance against chemotherapeutics or targeted therapies through either genetic mechanism or adaptive responses that commonly involve epigenetic reprogramming and activation of compensatory signaling pathways. Recent examples of such an adaptive response involve the treatment of BRAF mutant melanoma cancer patients with inhibitors of the BRAF/MAPK pathway. Several studies attribute it to a reversible cell state transition from a proliferative melanocytic state towards invasive neural crest-like and mesenchymal-like states. The capacity of certain BRAF mutant melanoma patient tumors, and the cell lines derived from them, to adapt to targeted therapies bears some conceptual similarities to adaptive responses obsd. in other cancers. Further, the response of the cells that adapt to BRAF inhibition is highly variable depending on phenotypic plasticity of the cells, the length of drug exposure, and the dosing strategy. As such, general physiochem. approaches that provide quant., predictive models of such transitions may provide a common conceptual framework for understanding the large genome-scale gene expression level changes. Through analyzing the kinetic trajectory of the reversible, adaptive response of a highly plastic, patient-derived BRAF^(V600) mutant melanoma cell line to BRAFi, using genome-wide expression of these cells at 15 time points over a period that included 29 days of drug treatment, followed by either an addnl. 30 days of treatment, or 35 days of drug release, we found that the cells adapt to the drug treatment in two stages, terminating in a mesenchymal-like state after almost a month of treatment. At that stage, continued drug exposure induced no further changes in cell phenotype. Following drug release, the cells reverted back to the original, drug naive phenotype, but the reverse pathway took a different trajectory than the forward pathway. Thermodynamically-motivated Surprisal Anal. was utilized to identify two constraints of this cyclic cell state transition to construct a free energy surface. A kinetic ODE model of the two unbalanced processes revealed that the process assocd. with the long-term adaptive transition was driven the other process reflective of a short-term drug stress response. Such kinetic model further allowed identifying driving transcription factors and epigenetic regulations that prompt the cyclic cell state transition towards adaptive resistance.


Item Type:Conference or Workshop Item (Paper)
Related URLs:
URLURL TypeDescription
https://global.acs.org/events/256th-acs-national-meeting-expositionOrganizationConference Website
ORCID:
AuthorORCID
Ng, Alphonsus0000-0003-0074-4598
Baltimore, David0000-0001-8723-8190
Heath, James R.0000-0001-5356-4385
Additional Information:© 2018 American Chemical Society.
Record Number:CaltechAUTHORS:20181109-142044662
Persistent URL:http://resolver.caltech.edu/CaltechAUTHORS:20181109-142044662
Usage Policy:No commercial reproduction, distribution, display or performance rights in this work are provided.
ID Code:90804
Collection:CaltechAUTHORS
Deposited By: Tony Diaz
Deposited On:13 Nov 2018 22:38
Last Modified:13 Nov 2018 22:38

Repository Staff Only: item control page